A significant decline was observed in PARP-1 and PARP-2 protein expression levels in tumors of both LC and LC-COPD patients compared to the respective non-tumor samples in both groups (Figure 3). The gene discussed is PARP1; the disease is laryngotracheoesophageal cleft.